Piramal Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 21,635.8 million compared to INR 21,313.6 million a year ago. Revenue was INR 21,880.8 million compared to INR 22,095 million a year ago. Net income was INR 501.1 million compared to INR 2,040.6 million a year ago. Basic earnings per share from continuing operations was INR 0.42 compared to INR 1.72 a year ago. Diluted earnings per share from continuing operations was INR 0.42 compared to INR 1.72 a year ago.
For the full year, sales was INR 70,815.5 million compared to INR 65,591 million a year ago. Revenue was INR 73,066.6 million compared to INR 68,349 million a year ago. Net loss was INR 1,864.6 million compared to net income of INR 3,759.6 million a year ago. Basic loss per share from continuing operations was INR 1.57 compared to basic earnings per share from continuing operations of INR 3.19 a year ago. Diluted loss per share from continuing operations was INR 1.57 compared to diluted earnings per share from continuing operations of INR 3.19 a year ago.